NITROMED, INC. REVISES SALES AND MARKETING STRATEGY; CUTS 120 JOBS

NitroMed, Inc. announced a revision of its strategy and business model in a move intended to focus its resources on the accelerated development of an extended release formulation of BiDil (isosorbide dinitrate/hydralazine hydrochloride), known as BiDil XR. This alternative strategy employs a less costly approach to marketing the current immediate release formulation of BiDil during BiDil XR's development that includes significantly reduced direct sales efforts. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=32712&full=1)